MedTrace Logo

A Long-term Study of the Safety of MK-0954A in Patients With Essential Hypertension (MK-0954A-351)

NCT01307033 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 278

Last updated 2024-05-17

Study results available
· View outcomes & findings →

Summary

This study is being conducted to evaluate the safety of MK-0954A (L100/H12.5 mg) in essential hypertension participants who are uncontrolled with MK-954H (L50/H12.5 mg).

Conditions

Interventions

DRUG

MK-0954A

Tablet containing losartan potassium (100 mg) and hydrochlorothiazide (12.5 mg), once daily

DRUG

MK-954H

Tablet containing losartan potassium (50 mg) and hydrochlorothiazide (12.5 mg), once daily

DRUG

Placebo to MK-0954A

Placebo tablet to match MK-0954A, once daily

DRUG

Placebo to MK-954H

Placebo tablet to match MK-954H, once daily

Sponsors & Collaborators

  • Organon and Co

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-03-29
Primary Completion
2012-12-04
Completion
2012-12-04

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01307033 on ClinicalTrials.gov